Wed May 22, 2013 9:46am EDT (Reuters) – Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with metastatic melanoma, a type of skin cancer. Shares of the Calgary-based company rose as much as 11 percent to C$3.14 on the Toronto Stock Exchange on Wednesday. Its Nasdaq-listed shares were up 10 percent. Reolysin was administered intravenously
(More)…
